Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives

被引：98
作者：
Aalders, Kim C. [1 ]
Tryfonidis, Konstantinos [1 ]
Senkus, Elbieta [2 ]
Cardoso, Fatima [3 ]
机构：
[1] European Org Res Treatment Canc, Dept Med, Brussels, Belgium
[2] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland
[3] Champalimaud Canc Ctr, Breast Unit, Lisbon, Portugal
来源：
CANCER TREATMENT REVIEWS | 2017年 / 53卷
关键词：
Angiogenesis; Breast cancer; Bevacizumab; VEGF; Sorafenib; Sunitinib; Ramucirumab; ENDOTHELIAL GROWTH-FACTOR; PHASE-III TRIAL; TYROSINE KINASE INHIBITOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; BEVACIZUMAB PLUS PACLITAXEL; OPEN-LABEL; 1ST-LINE TREATMENT; NEOADJUVANT CHEMOTHERAPY; TUMOR-CELLS; FACTOR VEGF;
D O I：
10.1016/j.ctrv.2016.12.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Angiogenesis is one of the hallmarks of cancer and a crucial requisite in the development of tumors. Interrupting this process by blocking the vascular endothelial growth factor (VEGF) with the monoclonal antibody bevacizumab has been considered a possible breakthrough in the treatment of various types of cancer, especially for advanced disease. However in breast cancer, studies have shown ambivalent results causing debate about the value of this drug. In this article, we review the evidence for anti-angiogenic treatment options for breast cancer, as well as discuss the possible factors limiting the effectiveness of anti-angiogenic agents and offer a recommendation regarding the future research on these therapies for the treatment of breast cancer. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码：98 / 110
页数：13
相关论文
共 127 条
[1]  
André T, 2000, INT J CANCER, V86, P174, DOI 10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.3.CO
[2]  
2-5
[3]   New Insights into Molecular Mechanisms of Sunitinib-Associated Side Effects [J].
Aparicio-Gallego, Guadalupe ;
Blanco, Moises ;
Figueroa, Angelica ;
Garcia-Campelo, Rosario ;
Valladares-Ayerbes, Manuel ;
Grande-Pulido, Enrique ;
Anton-Aparicio, Luis .
MOLECULAR CANCER THERAPEUTICS, 2011, 10 (12) :2215-2223
[4]  
Bando H, 2007, BREAST CANC, P14
[5]  
Barr MP, 2008, INT J ONCOL, V32, P41
[6]   Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer [J].
Barrios, Carlos H. ;
Liu, Mei-Ching ;
Lee, Soo Chin ;
Vanlemmens, Laurence ;
Ferrero, Jean-Marc ;
Tabei, Toshio ;
Pivot, Xavier ;
Iwata, Hiroji ;
Aogi, Kenjiro ;
Lugo-Quintana, Roberto ;
Harbeck, Nadia ;
Brickman, Marla J. ;
Zhang, Ke ;
Kern, Kenneth A. ;
Martin, Miguel .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 121 (01) :121-131
[7]   Bevacizumab: no comeback in early breast cancer? [J].
Bartsch, Rupert ;
Gnant, Michael ;
Steger, Guenther G. .
LANCET ONCOLOGY, 2015, 16 (09) :1001-1003
[8]  
Baselga J, 2014, ANN ONCOL, V25
[9]   A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial [J].
Baselga, Jose ;
Costa, Frederico ;
Gomez, Henry ;
Hudis, Clifford A. ;
Rapoport, Bernardo ;
Roche, Henri ;
Schwartzberg, Lee S. ;
Petrenciuc, Oana ;
Shan, Minghua ;
Gradishar, William J. .
TRIALS, 2013, 14
[10]   Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer [J].
Baselga, Jose ;
Martins Segalla, Jose Getulio ;
Roche, Henri ;
del Giglio, Auro ;
Pinczowski, Helio ;
Ciruelos, Eva M. ;
Cabral Filho, Sebastiao ;
Gomez, Patricia ;
Van Eyll, Brigitte ;
Bermejo, Begona ;
Llombart, Antonio ;
Garicochea, Bernardo ;
Climent Duran, Miguel Angel ;
Gehm Hoff, Paulo Marcelo ;
Espie, Marc ;
Junior Gemeinder de Moraes, Andre Augusto ;
Ribeiro, Ronaldo Albuquerque ;
Mathias, Clarissa ;
Gil Gil, Miguel ;
Ojeda, Belen ;
Morales, Josefa ;
Ro, Sunhee Kwon ;
Li, Shell ;
Costa, Frederico .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (13) :1484-1491
12345678910